October 7, 2025 — Leads & Copy — GenSight Biologics (Euronext: SIGHT), a biopharma company focused on developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced its cash position as of September 30, 2025.
The company’s cash and cash equivalents totaled €0.6 million as of September 30, 2025, compared to €0.3 million as of June 30, 2025. On October 1, 2025, GenSight Biologics received €3.0 million from a fundraising completed on September 26, 2025, net of a €0.7 million repayment on convertible bonds held by Heights Capital. As of October 1, 2025, the company’s cash and cash equivalents totaled €3.6 million.
GenSight Biologics has sufficient net working capital to meet its obligations only until the end of the fourth quarter of 2025. However, a positive regulatory decision before the end of the year could extend the cash runway to the end of May 2026. The management’s plan and financing strategy presented in the HY 2025 Financial Statement press release issued on September 29, 2025, remains valid. As of October 1, 2025, GenSight Biologics had 174,475,604 outstanding ordinary shares.
GenSight Biologics S.A. is focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Its pipeline leverages the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. The company’s lead product candidate, GS010 (lenadogene nolparvovec), is in Phase III in Leber Hereditary Optic Neuropathy (LHON). GS010 is currently in clinical development and has not been granted marketing authorization in France or any other jurisdiction.
